New designer drug, 2,5-dimethoxy-4-propylthio-β-phenethylamine (2C-T-7): Studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry

Journal of Mass Spectrometry

Volumn 40, Issue 1, 2005, Pages 105-116

  Theobald, Denis S ^a   Fehn, Susanna ^b   Maurer, Hans H ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b Kriminaltechnisches Institut   (Germany)

Author keywords

2,5 dimethoxy 4 propylthio phenethylamine; 2C T 7; Metabolism; gas chromatography mass spectrometry; Urinalysis

Indexed keywords

ACETYLATION; AMINES; EXTRACTION; GAS CHROMATOGRAPHY; HYDROLYSIS; HYDROXYLATION; MASS SPECTROMETRY; METABOLISM; METABOLITES; OXIDATION; REDUCTION;

DEAMINATION; RAT URINE; SULFOXIDATION; SYSTEMATIC TOXICOLOGICAL ANALYSIS (STA);

DRUG PRODUCTS;

2,5 DIMETHOXY 4 PROPYLTHIO BETA PHENETHYLAMINE; DESIGNER DRUG; PHENETHYLAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; CONFERENCE PAPER; DEALKYLATION; DEAMINATION; DRUG ACETYLATION; DRUG DETERMINATION; DRUG HYDROLYSIS; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; GAS CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; MASS SPECTROMETRY; METHYLATION; MICROWAVE RADIATION; NONHUMAN; PRIORITY JOURNAL; RAT; REACTION ANALYSIS; SULFOXIDATION; TOXICOLOGY; URINALYSIS;

ADMINISTRATION, ORAL; ANIMALS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; PHENETHYLAMINES; RATS; RATS, WISTAR; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS;

EID: 13244279850     PISSN: 10765174     EISSN: None     Source Type: Journal    
DOI: 10.1002/jms.784     Document Type: Conference Paper

References (56)

1. Shulgin A. In Pihkal, a Chemical Love Story, Joy D (ed). Transform Press: Berkeley, CA, 1991; 815.
2. de Boer D, Bosman I. A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs. Pharm. World Sci. 2004; 26: 110.
3. The vaults of Erowid documenting the complex relationship between humans and psychoactives. www. erowid. org 2004.
4. Drug Enforcement Administration-Department of Justice. Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-benzylpiperazine into Schedule I of the Controlled Substances Act. Fed. Regist. 2004; 69: 12794.
5. European Communities. Council Decision 2003/847/JHA of 27 November 2003 concerning control measures and criminal sanctions in respect of the new synthetic drug 2C-I, 2C-T-2, 2C-T-7 and TMA-2. Off. J. Eur. Commun. 2003; L321: 64.
6. Drug Enforcement Administration-Office of Forensic Sciences. 2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7). Microgram 2001; 34: 193.
7. Drug Enforcement Administration-Office of Forensic Sciences. Numerous analogs in southeastern Wisconsin. Microgram 2000; 33: 309.
8. Curtis B, Kemp P, Harty L, Choi C, Christensen D. Postmortem identification and quantitation of 2,5-dimethoxy-4-n-propylthiophenethylamine using GC-MSD and GC-NPD. J. Anal. Toxicol. 2003; 27: 493.
9. 125I]-2C-I) as a label for the 5-HT2 receptor in rat frontal cortex. Pharmacol. Biochem. Behav. 1990; 35: 211.
10. Glennon RA, Raghupathi R, Bartyzel P, Teitler M, Leonhardt S. Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity. J. Med. Chem. 1992; 35: 734.
11. Glennon RA, Titeler M, Lyon RA. A preliminary investigation of the psychoactive agent 4-bromo-2,5-dimethoxyphenethylamine: a potential drug of abuse. Pharmacol Biochem. Behav. 1988; 30: 597.
12. Monte AP, Marona-Lewicka D, Parker MA, Wainscott DB, Nelson DL, Nichols DE. Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups. J. Med. Chem. 1996; 39: 2953.
13. Acuna-Castillo C, Villalobos C, Moya PR, Saez P, Cassels BK, Huidobro-Toro JP. Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT(2A) and 5-HT(2C) receptors. Br. J. Pharmacol. 2002; 136: 510.
14. Villalobos CA, Bull P, Saez P, Cassels BK, Huidobro-Toro JP. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes. Br. J. Pharmacol. 2004; 141: 1167.
15. Giroud C, Augsburger M, Rivier L, Mangin P, Sadeghipour F, Varesio E, Veuthey JL, Kamalaprija P. 2C-B: a new psychoactive phenylethylamine recently discovered in Ecstasy tablets sold on the Swiss black market. J. Anal. Toxicol. 1998; 22: 345.
16. Cole MD, Lea C, Oxley N. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): a review of the public domain literature. Sci. Justice 2002; 42: 223.
17. de Boer D, Gijzels MJ, Bosman IJ, Maes RA. More data about the new psychoactive drug 2C-B [letter; comment]. J. Anal. Toxicol. 1999; 23: 227.
18. Bosman IJ, de Boer D, Siderius EB, Lesseps JALdR, Maes RAA. In Proceedings of the 1998 Joint SOFT/TIAFT Meeting, TIAFT98, Spiehler V (ed). Albuquerque, NM, 1999; 355.
19. DeRuiter J, Clark CR, Noggle FT. LC and GC-MS analysis of 4-bromo-2,5-dimethoxyphenethylamine (Nexus) and 2-propanamine and 2-butanamine analogs. J. Chromatogr. Sci. 1995; 33: 583.
20. DeRuiter J, Clark CR, Noggle FT. Gas chromatographic-mass spectrometric and high-performance liquid Chromatographic analyses of the bromination products of the regioisomeric dimethoxyphenethylamines: differentiation of Nexus from five positional isomers. J. Chromatogr. Sci. 1998; 36: 23.
21. Ragan FA Jr, Hite SA, Samuels MS, Garey RE. 4-Bromo-2,5- dimethoxyphenethylamine: identification of a new street drug. J. Anal. Toxicol. 1985; 9: 91.
22. de Boer D, Lesseps JALdR, Gijzelsm M, Pilon N, Bosman IJ, Maes RAA. In Proceedings of the 1998 Joint SOFT/TIAFT Meeting, TIAFT98, Spiehler V (ed). Albuquerque, NM, 1999; 352.
23. Kanamori T, Inoue H, Iwata Y, Ohmae Y, Kishi T. In vivo metabolism of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in the rat: identification of urinary metabolites. J. Anal. Toxicol. 2002; 26: 61.
24. Lin LC, Liu JT, Chou SH, Lin CH. Identification of 2,5-dimethoxy-4- ethylthiophenethylamine and its metabolites in the urine of rats by gas chromatography-mass spectrometry. J. Chromatogr. B 2003; 798: 241.
25. Kanamori T, Tsujikawa K, Ohmae Y, Iwata Y, Inoue H, Inouye Y, Kishi T. Excretory profile of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rat. J. Health Sci. 2003; 49: 166.
26. Staack RF, Maurer HH. New designer drug 1-(3,4-methylenedioxybenzyl) piperazine (MDBP): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J. Mass Spectrom. 2004; 39: 255.
27. Staack RF, Fritschi G, Maurer HH. Studies on the metabolism and the toxicological analysis of the new piperazine-like designer drug N-benzylpiperazine in urine using gas chromatography-mass spectrometry. J. Chromatogr. B 2002; 773: 35.
28. Staack RF, Fehn J, Maurer HH. New designer drug paramethoxymethamphetamine: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry. J. Chromatogr. B 2003; 789: 27.
29. Maurer HH, Bickeboeller-Friedrich J. Screening procedure for detection of antidepressants of the selective serotonin reuptake inhibitor type and their metabolites in urine as part of a modified systematic toxicological analysis procedure using gas chromatography-mass spectrometry. J. Anal. Toxicol. 2000; 24: 340.
30. Bickeboeller-Friedrich J, Maurer HH. Screening for detection of new antidepressants, neuroleptics, hypnotics, and their metabolites in urine by GC-MS developed using rat liver microsomes. Ther. Drug Monit. 2001; 23: 61.
31. McKay AF, Ott WL, Taylor GW, Buchanan MN, Crooker JF. Diazohydrocarbons. Can. J. Res. 1950; 28: 683.
32. Pfleger K, Maurer HH, Weber A. Mass Spectral Library of Drugs, Poisons, Pesticides, Pollutants and their Metabolites (4th edn). Agilent Technologies: Palo Alto, CA, in preparation.
33. Maurer HH. In Mass Spectral and GC Data of Drugs, Poisons, Pesticides, Pollutants and their Metabolites, Pfleger K, Maurer HH, Weber A (eds). VCH: Weinheim, 1992; 21.
34. Staack RF, Theobald DS, Maurer HH. Studies on the human metabolism and the toxicologic detection of the cough suppressant dropropizine in urine using gas chromatography-mass spectrometry. Ther. Drug Monit. 2004; 26: 441.
35. Staack RF, Maurer HH. Studies on the metabolism and the toxicological analysis of the nootropic drug fipexide in rat urine using gas chromatography-mass spectrometry. J. Chromatogr. B 2004; 804: 337.
36. Paul LD, Maurer HH. Studies on the metabolism and toxicological detection of the Eschscholtzia californica alkaloids californine and protopine in urine using gas chromatography-mass spectrometry. J. Chromatogr. B 2003; 789: 43.
37. Staack RF, Fritschi G, Maurer HH. New designer drug 1-(3- trifluoromethylphenyl)piperazine (TFMPP): gas chromatography/mass spectrometry and liquid chromatography/mass spectrometry studies on its phase I and II metabolism and on its toxicological detection in rat urine. J. Mass Spectrom. 2003; 38: 971.
38. Staack RF, Maurer HH. Piperazine-derived designer drug 1-(3-chlorophenyl)piperazine (mCPP): GC-MS studies on its metabolism and its toxicological detection in urine including analytical differentiation from its precursor drugs trazodone and nefazodone. J. Anal. Toxicol. 2003; 27: 560.
39. Kraemer T, Bickeboeller-Friedrich J, Maurer HH. On the metabolism of the amphetamine-derived antispasmodic drug mebeverine: gas chromatography-mass spectrometry studies on rat liver microsomes and on human urine. Drug Metab. Dispos. 2000; 28: 339.
40. McLafferty FW, Turecek F, Interpretation of Mass Spectra (4th edn). University Science Books: Mill Valley, CA, 1993.
41. Smith RM, Busch KL, Understanding Mass Spectra - a Basic Approach, Wiley: New York, 1999.
42. Theobald DS, Staack RF, Puetz M, Maurer HH. New designer drug 2,5-dimethoxy-4-ethylthio-β-phenethylamine (2C-T-2): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J. Mass Spectrom. in preparation.
43. Farber TM. Enzymatic S-de-ethylation and the mechanism of S-dealkylation. Proc. Soc. Exp. Biol. Med. 1975; 149: 13.
44. Ames MM, Selassie CD, Woodson LC, Van Loon JA, Mansch C, Weinshilboum RM. Thiopurine methyltransferase: structure-activity relationships for benzoic acid inhibitors and thiophenol substrates. J. Med. Chem. 1986; 29: 354.
45. Woodson LC, Ames MM, Selassie CD, Mansch C, Weinshilboum RM. Thiopurine methyltransferase. Aromatic thiol substrates and inhibition by benzoic acid derivatives. Mol. Pharmacol. 1983; 24: 471.
46. McBain JB, Menn JJ. S-Methylation, oxidation, hydroxylation and conjugation of thiophenol in the rat. Biochem. Pharmacol. 1969; 18: 2282.
47. Maurer HH. Screening procedures for simultaneous detection of several drug classes used in the high throughput toxicological analysis and doping control [review]. Comb. Chem. High Throughput Screen. 2000; 3: 461.
48. Maurer HH, Kraemer T. Toxicological detection of selegiline and its metabolites in urine using fluorescence polarization immunoassay (FPIA) and gas chromatography-mass spectrometry (GC-MS) and differentiation by enantioselective GC-MS of the intake of selegiline from abuse of methamphetamine or amphetamine. Arch. Toxicol. 1992; 66: 675.
49. Ensslin HK, Kovar KA, Maurer HH. Toxicological detection of the designer drug 3,4-methylenedioxyethylamphetamine (MDE, 'Eve') and its metabolites in urine by gas chromatography-mass spectrometry and fluorescence polarization immunoassay. J. Chromatogr. B 1996; 683: 189.
50. Ensslin HK, Maurer HH, Gouzoulis E, Hermle L, Kovar KA. Metabolism of racemic 3,4-methylenedioxyethylamphetamine in humans. Isolation, identification, quantification, and synthesis of urinary metabolites. Drug Metab. Dispos. 1996; 24: 813.
51. Maurer HH. On the metabolism and the toxicological analysis of methylenedioxyphenylalkylamine designer drugs by gas chromatography-mass spectrometry. Ther. Drug Monit. 1996; 18: 465.
52. Kraemer T, Vernaleken I, Maurer HH. Studies on the metabolism and toxicological detection of the amphetamine-like anorectic mefenorex in human urine by gas chromatography-mass spectrometry and fluorescence polarization immunoassay. J. Chromatogr. B 1997; 702: 93.
53. Kraemer T, Maurer HH. Determination of amphetamine, methamphetamine and amphetamine-derived designer drugs or medicaments in blood and urine [review]. J. Chromatogr. B 1998; 713: 163.
54. Kováts E. Gaschromatographische Charakterisierung organischer Verbindungen. Teil 1. Retentionsindices aliphatischer Halogenide, Alkohole, Aldehyde und Ketone. Helv. Chim. Acta 1958; 41: 1915.
55. de-Zeeuw RA, Franke JP, Maurer HH, Pfleger K, Gas Chromatographic Retention Indices of Toxicologically Relevant Substances and their Metabolites (Report of the DFG Commission for Clinical Toxicological Analysis, Special Issue of the TIAFT Bulletin) (3rd edn). VCH: Weinheim, 1992.
56. Staack RF, Maurer HH. Toxicological detection of the new designer drug 1-(4-methoxyphenyl)piperazine and its metabolites in urine and differentiation from an intake of structurally related medicaments using gas chromatography-mass spectrometry. J. Chromatogr. B 2003; 798: 333.